Clinical Trial Update: A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases [Phase 2]

View source ↗

Summary

This Phase 2 master protocol trial, sponsored by Amgen, is evaluating Inebilizumab and Blinatumomab in autoimmune diseases. It is currently recruiting and inclu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis
• Systemic Lupus Erythematosus

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)
• Uplizna (inebilizumab)

Snippet

Sponsor: Amgen | Conditions: Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis | Phase 2 | Status: RECRUITING